Skip to main content
main-content

Cardiovascular disorders


Browse the latest news, expert commentary, and educational content on cardiovascular disorders.


Highlights

Piggy bank balancing on seesaw over a bottle of pills

10-04-2022 | Healthcare costs | News

First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

Clinician holding a clear tablet with a heart image - cardiovascular research concept

08-31-2022 | Heart failure | News

‘Strikingly consistent’ evidence for SGLT2 inhibitor benefits across the spectrum of heart failure

SGLT2 inhibitors reduce the risk for adverse outcomes in a broad range of patients with heart failure, suggest findings from a meta-analysis of five randomized placebo-controlled trials.

Doctor measuring arterial blood pressure on arm of a patient

07-28-2022 | Anti-hypertensive medications | News

No justification for bespoke antihypertensive intervention in type 2 diabetes

The absolute benefit of blood pressure reduction on cardiovascular risk does not differ according to whether or not people have type 2 diabetes, shows an individual participant data meta-analysis.

More on cardiovascular disorders

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox